• ANI Pharmaceuticals posted Q2 2026 net revenues of $266 million, up 25.9% year over year.
• Net income available to common shareholders rose to $24.7 million; diluted GAAP EPS increased to $1.05.
• Adjusted non-GAAP EBITDA climbed to $71.6 million, up 32.4%.
• Cortrophin Gel net revenues jumped to $117.1 million, up 43.5%; ILUVIEN net revenues fell to $18.7 million, down 16.1% on timing of international shipments.
• Reaffirmed 2026 net revenue guidance of $1.08 billion-$1.14 billion; cut Cortrophin Gel net revenue outlook to $520 million-$540 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070650PRIMZONEFULLFEED9805767) on August 07, 2026, and is solely responsible for the information contained therein.